Neonatal Spinal Muscular Atrophy (SMA) Screening

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-2
SponsorKaohsiung Medical University Chung-Ho Memorial Hospital

About this trial

Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening test, further confirmation with multiplex ligation-dependent probe amplification (MLPA) test and prospective motor function monitoring including physical and neurological examinations will be proved to make SMA confirmation. For any confirmed SMA patient, genetic counseling and standard of care will be proved.

Eligibility criteria

Qualifiers

Neonates born in Taiwan who receive regular newborn screening suggested by Ministry of Heath and Welfare.

Parents or legal guardian agree to perform SMA newborn screening.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • SMA Newborn Screening

Treatment groups

No treatment groups listed

Sponsors and collaborators

Kaohsiung Medical University Chung-Ho Memorial Hospital

Lead sponsor

The Chinese Foundation of Health

Collaborator

Taipei Institute of Pathology

Collaborator